(firstQuint)A Study of EDP-938 in Healthy Subjects.

 The first phase assesses single ascending doses for EDP-938 (active drug or placebo) in healthy subjects.

 A "fasted" and "fed" two-part cohort will also assess food effect.

 The second phase assesses multiple ascending doses (active drug or placebo) for 7-days in healthy subjects.

 Each cohort within each phase will enroll a total of 8 subjects who will be randomized to receive EDP-938 or placebo.

 The cohort assessing food effect will enroll 10 subjects randomized to receive EDP-938 or placebo.

.

 A Study of EDP-938 in Healthy Subjects@highlight

This randomized, double-blind, placebo-controlled study will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-938 in healthy adult subjects